FOLH1 and neoplasm: Therefore, the modification of the canonical amide bond of DCFPyL to include an alkyl chain and oxime-linked [18F]fluorobenzyl or -pyridinyl substituent minimally affected in vivo tumor targeting to PSMA, indicating that in human patients, all four [18F]DCFPyL analogues would be expected to identify PSMA expressing lesions as has been clinically observed with [18F]DCFPyL [45].